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Surgery of pulmonary aspergillomas in
immunocompromised patients
Chirurgie des pulmonalen Aspergilloms bei immunsupprimierten
Patienten
Abstract
Introduction: Pulmonary aspergillosis is a devastating complication in
immunocompromised patients. Timing of surgery is controversial and
depends on the patients' general condition.
B. Kosan
1
V. Steger
1
T. Walker
2
Methods: From 2000 to 2007, 16 patients (mean age 47 years, range
20–64)underwentsurgeryforpulmonaryaspergillosis.Allpatientswere G. Friedel
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receiving immunosuppressive drugs due to chemotherapy of hemato- H. Aebert
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logical malignancies, ten with additional bone marrow or stem cell
transplantation.Perioperatively,aspergillosiswastreatedwithantifungal
agents. If granulocyte numbers in the peripheral blood was below 1 Department of Thoracic
Surgery, Schillerhoehe
Hospital,Gerlingen,Germany
1.0x10
9/l, granulocyte stimulating factor and granulocyte transfusions
were administered perioperatively.
Results: Four patients underwent lobectomy and wedge resections of
the same lung, one patient bilobectomy, two patients lobectomy, eight
2 Eberhard-Karls-University,
University Hospital
Tuebingen, Germany patientswedgeresectionsofonelung,andonepatientwedgeresections
ofbothlungs.Allpatientssurvivedsurgerywithoutmajorcomplications.
Five patients were bone marrow or stem cell transplanted 1, 2, 3, 7
and 10 months after surgery. Three of them died due to recurrence of
theunderlyingmalignancy.Allotherpatientsarealiveandfreeoffungal
disease.
Conclusions: Timing of surgery in the context of antifungal therapy and
adequatenumbersofgranulocytesandplateletsintheperipheralblood
appearessentialforsuccessfulsurgicaltherapyandavoidanceofmajor
complications.
Keywords: thoracic surgery, pulmonary aspergillosis,
immunosuppression, bone marrow transplantation, hematological
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Zusammenfassung
Hintergrund:BeiimmunsupprimiertenPatientenstelltdieLungenasper-
gillose eine schwere Komplikation dar. Der richtige Zeitpunkt der ope-
rativen Therapie wird nach wie vor kontrovers diskutiert und hängt im
Wesentlichen vom Allgemeinzustand des Patienten ab.
Methoden: Zwischen 2000 und 2007 wurden 16 Patienten (Alter zwi-
schen20–64Jahren,mittleresAlter47Jahre)aufgrundeinerpulmona-
len Aspergillose einer operativen Therapie zugeführt. Alle Patienten er-
hielten infolge einer hämato-onkologischen Grunderkrankung eine
ChemotherapieodereineimmunsuppressiveTherapie.ZehnPatienten
hattenbereitseineKnochenmark-bzw.eineStammzelltransplantation.
PerioperativwurdedieantimykotischeTherapieununterbrochenfortge-
führt. Bei einer Granulozytenzahl unter 1,0x10
9/l im peripheren Blut
wurden perioperativ Granulozyten-stimulierender Faktor und Granulo-
zyten substituiert.
Ergebnisse: Bei vier Patienten wurde eine Lobektomie mit zusätzlicher
Keilresektion in einem ipsilateralen Lungenlappen durchgeführt. Bei
einem Patienten erfolgte eine Bilobektomie, bei zwei Patienten eine
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nem weiteren Patienten Keilresektionen bilateral. Alle Patienten über-
standen die operative Therapie ohne große Komplikationen.
Schlussfolgerung: Der richtige Zeitpunkt der chirurgischen Therapie im
EinklangmitderantimykotischenTherapieundausreichenderGranulo-
zyten-undThrombozytenzahlimperipherenBlutistfüreineerfolgreiche
chirurgischeTherapieundzurVermeidungvonschwerenKomplikationen
essentiell.
Schlüsselwörter: Thoraxchirurgie, Pulmonale Aspergillose,
Immunsuppression, hämatologische Malignome,
Knochenmarkstransplantation
Introduction
Aspergillus is a saprophytic ubiquitous environmental
fungus, which is normally found in soil, decaying vegeta-
tion and dust. There are more than 1000 species of As-
pergillus organisms. However, only Aspergillus niger, fu-
migatusandflavusarepathogenic[1].Ingeneral,pulmon-
ary aspergillosis is classified as allergic, invasive and/or
saprophytic infection. Invasive pulmonary aspergillosis
isasevereandlife-threateningdiseasewhichisobserved
inimmunocompromisedpatients,whileallergicbroncho-
pulmonary aspergillosis is a hypersensitivity reaction to
Aspergillus antigens that mainly affects patients with
asthma [2], [3].
Inimmunocompromisedpatientsaspergillusspeciesmay
grow invasively or colonize preexisting lung cavities and
produce a fungus ball or an aspergilloma [4] (Figure 1).
Figure 1: Computed tomogram of the chest: Aspergilloma
within a cavern and thickend surrounding wall of the left lung.
Surgery consisted of thoracotomy and lobectomy.
The clinical and morphological manifestation of a patho-
logic aspergillus infection mainly depends on lung struc-
ture with preexisting caverns and the host immune re-
sponse [5]. Untreated, it may cause life-threatening
complications after immunosuppression, especially in
patients with underlying hematological malignancies [6].
Although new prospective screening methods for early
diagnosis have been developed in recent years, invasive
aspergillosis remains a challenging problem in immuno-
compromised patients [7], [8], [9], [10]. Over the last few
years,promisingantifungaltherapyregimenswereestab-
lished [11], [12], [13], [14], [15]. However, surgery may
still be necessary for the elimination of the fungus reser-
voir before bone marrow transplantation or because of
alackofpharmacologicalfunguscontrolinimmunocom-
promised patients. Particularly, the timing of surgery is
controversial due to the high incidence of perioperative
mortality and morbidity, depending on the patients' gen-
eral condition [16], [17], [18], [19].
Design and methods
Sixteenpatientsunderwentsurgicaltherapyforpulmonary
aspergillosis between September 2000 and April 2007.
Two female and fourteen male patients with a mean age
of 47 years (range 20 to 64 years), were referred from
the Department of Hematology and Oncology and admit-
ted to the Department of Thoracic, Cardiac and Vascular
Surgery. All patients had formation of caverns due to
necrotizing pulmonary aspergillosis. All patients were re-
ceiving immunosuppressive drugs for chemotherapy of
a hematological malignancy; nine with acute leukemia
(seven with acute myelocytic leukemia, one with B- and
one with T-acute lymphatic leukemia), three with a B-
chronic lymphatic leukemia, two with M. Hodgkin, one
with a myelodysplastic syndrome and one with chronic
myelocytic leukemia. Three of the patients had already
received allogenic bone marrow transplantation and two
other patients stem cell transplantation (Table 1). The
diagnosis of aspergillus infection was initially suspected
inallpatientsbychestX-raysandcomputedtomography.
It was confirmed by cultures from bronchial lavage and
PCR-investigations, respectively. Preoperatively, seven
patients had moderate hemoptysis, however, no patient
required an acute intervention such as bronchoscopy or
surgery and no blood transfusion was needed. Cough,
fever and other nonspecific signs of infection were ob-
served in eleven patients, with five patients being
asymptomatic.Allpatientsreceivedantifungalchemother-
apy perioperatively, seven with liposomal amphotericin
B;onepatientliposomalamphotericinBadditionallywith
itraconazole and three patients were treated with lipo-
somal amphotericin B and caspofungin, one patient with
caspofunginandfourpatientswithvoriconazole.Conven-
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or stem cell transplantation (SCT). m: male, f: female. MDS: myelodysplastic syndrome, CLL: chronic lymphatic leukemia, CML:
chronic myelocytic leukemia, ALL: acute lymphatic leukemia, AML: acute myelocytic leukemia.
tional chest X-ray and computed tomography investiga-
tions were performed in order to evaluate the antifungal
therapy before surgery and the postoperative status.
Every effort was made to improve the general condition
of the patients preoperatively, including physical and
respiratory training. In two patients, surgery was post-
poned for three and four weeks to improve respiratory
function. Surgery was not performed when the neutro-
philic counts were below 1.0x10
9/l. In these patients,
granulocyte colony stimulating factor (GCSF) was given
and if this did not succeed neutrophilic granulocyte
transfusionswereadministeredperioperatively[20],[21],
[22].
Theaimofsurgerywastoremoveeverysiteofaspergillus
infection. If necessary, concomitant surgery of other in-
fected areas like the paranasal sinuses was performed.
Care was taken to remove the pulmonary aspergillomas
in toto and to avoid spillage of infected tissue to the
pleural space. Pharmacological therapy was continued
in the perioperative phase.
During the operation, all palpable tumors were resected.
In all cases, surgical resection was performed to achieve
localcontroloftheinfectionandremoveinfectedcaverns
as a potential infectious focus for systemic spreading.
Surgical specimens were cultured and examined
postoperatively by standard pathological techniques.
Results
Sixteenimmunocompromisedpatientsunderwentseven-
teen operations. The mean interval from diagnosis of
aspergillosis to surgery was 116 days, range 7 to 475
days (Table 2). All patients tolerated surgery well, there
werenoperioperativemortalitiesandnosignificantmajor
surgeryrelatedcomplications,likeempyema,hemorrhage
orbronchialfistula.Intwopatients,prolongedchesttube
drainage longer than 7 days was necessary. In one case,
due to an air leak for eight days and in the other case,
for twelve days because of a recurring pleural effusion.
Two patients developed pleural effusion after removal of
the chest tubes which was evacuated by percutaneous
aspiration (Table 3).
The average lesion resected measured 41 mm (range
22–65 mm) in diameter. Altogether, seven patients re-
quiered lobectomies: one patient underwent a bilobec-
tomy,threeasinglelobectomy(oneofthemwiththoraco-
plasty) and three patients lobectomy combined with a
wedgeresectionofthesamelung.Infivepatientsasingle
wedge resection was performed while in three patients
multiple wedge resections of the same lung were neces-
sary. One patient required two wedge resections of both
lungs in two different operations. In one patient who
underwent lobectomy and wedge resection, a simultan-
eous pansinectomy was performed for associated asper-
gillus pansinusitis (Table 2). One patient had to undergo
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and quantity of lung resection
neurosurgerybecauseofintracerebralaspergillosiseight
months after lung surgery.
Pathohistology revealed vital fungal hyphae in the lung
caverns of twelve patients. In four patients, the fungal
infectioncouldnotbeverifiedbyhistology,however,PCR-
assays of resected tissue showed aspergillus DNA se-
quences.
Primary bone marrow transplantation and stem cell
transplantation was carried out in five patients one, two,
three, seven and ten months after pulmonary surgery,
respectively. One of these patients died three months
after surgery due to an early rejection of the stem cell
grafts.Anotherpatientdiedduetograftversushostreac-
tion 16 months after lung surgery and 34 months after
bone marrow transplantation. The third patient died due
to rejection of the stem cell grafts 4 months after lung
surgery and 5 months after stem cell transplantation. All
other patients are still alive and have no evidence of as-
pergillus infection (Table 3).
The average platelet count at the time of the operation
was154x10
9/l(range63–275x10
9/l).Theaverageabso-
lute leukocyte and neutrophil counts at the time of the
operation was 7.0x10
9/l (range 3.1–12.3x10
9/l), and
4.8x10
9/l (range 1.2–8.7x10
9/l), respectively. In two
cases granulocyte colony stimulating factor and in one
patient granulocyte transfusions were administered
perioperatively.Inonepatientplateletsweresubstituded
preoperatively (Table 4).
Pulmonary function tests were performed in all patients
preoperatively.Sixpatientshadarestrictivelungdisease
withanFVCof3.2to4.1l(56–67%),fourfurtherpatients
showed a combined obstruction: FEV 1: 1.8 to 2.9 l,
(54–65%). Other important concomitant diseases were
reactivated tuberculosis in one patient and aortic valve
stenosis requiring aortic valve replacement 21 months
later in another patient. Nine patients had an elevated
serum creatinine level (1.3 to 1.9 mg/dl).
Discussion
Aspergillosisisapotentiallyfatalcomplicationinimmuno-
compromised patients [23], [24]. This infection has even
become a major cause of mortality in patients after allo-
geneic stem cell transplantation [25]. Once clinically
suspected,invasiveaspergillosisneedsantifungaltherapy
to be initiated immediately [26]. In recent years new
screeningmethodsofaspergillusinfectionandpromising
antifungal therapy regimens were established in many
centres and published [27], [28], [29], [30]. In spite of
theimprovementofdrugtherapyforinvasiveaspergillosis
themortalityratestillremainshigh,rangingfrom35–75%
[31], [32]. Approximately 50% of patients show an ad-
equate response to drug therapy. Surgical therapy and
its timing still remains controversial. Poor general condi-
tion of the patient, neutropenia, thrombocytopenia and
4/8 GMS Thoracic Surgical Science 2010, Vol. 7, ISSN 1862-4006
Kosan et al.: Surgery of pulmonary aspergillomas in immunocompromised ...Table 3: Perioperative complications and patients' outcome. GvHD: graft versus host disease. m: male, f: female. AML: acute
myelocytic leukemia
persistantmalignancyusuallyresultinhighmorbidityand
mortality. In the literature, perioperative mortality varies
between 14% and 32% [6], [17], [21], [25], [33], [34],
[35]. In our experience, no perioperative death and only
minor complications such as prolonged chest tube
drainagewereobserved.Threelatedeathswereunrelated
to aspergillosis and to surgery. All other patients are still
alive and have no evidence of aspergillus infection.
Complete resection of aspergilloma eliminates fungal
focus and prevents relapse during further immunosup-
pressive therapies. Five patients underwent allogenic
bonemarrowtransplantationorstemcelltransplantation
within a few months after lung surgery, respectively.
In all of our patients infection could be eliminated with
combinedsurgicalresectionofaspergillomaandsystemic
antifungaltherapyashasbeenpreviouslypublished[17],
[36], [37], [38], [39]. Perioperative complications seem
to be directly correlated to the number of neutrophils in
the peripheral blood. Therefore, we attribute our low in-
cidence of complications to sufficient peripheral neutro-
phil counts (>1.0x10
9/l), careful surgical technique and
intensive perioperative physical therapy.
Inconclusion,wemayemphasizethatparenchymasaving
lungresectionofpulmonaryaspergillomaisanadequate
therapy with minor perioperative complications even in
immunocompromized patients. These include patients
receiving chemotherapy for hematological malignancies
and patients after bone marrow or stem cell transplanta-
tion. The aim of surgery is to eliminate a potential source
ofinfectionunderhigh-doseimmunosuppressivetherapy.
In addition, granulocyte colony stimulating factor,
granulocytes and thrombocytes should be substituted
adequately, if necessary [17]. Antifungal therapy periop-
erativelyappearsimportanttopreventarelapseofasper-
gillosis. Multimodal and interdisciplinary treatment as
shown in this group of patients, may help to reduce mor-
bidityandmortalityofpulmonaryaspergillosisinimmuno-
compromised patients.
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